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Abstract: Alkylation of the 5-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-(3/4-me-
thylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones 3a,b with various alkyla-
tion agents, i.e., ethyl bromide, phenacyl bromide and ethyl chloroacetate, 
afforded the S-substituted 1,2,4-triazoles 4-6a,b. The structures of these new 
compounds were elucidated by elemental analysis and IR, UV, 1H-NMR, 13C- 
-NMR and MS spectroscopy. The newly synthesized products were tested for 
their antibacterial effects. 
Keywords: alkylation; 1,2,4-triazole-3-thione; antibacterial activity. 
INTRODUCTION 
A large number of bioactive molecules contain a functionalized 1,2,4-triazo-
le nucleus. Various compounds containing the 1,2,4-triazole ring are well known 
as drugs. For example, fluconazole, itraconazole and voriconazole are used as an-
timicrobial drugs;1 ribavirin has antiviral action,2 while vorozole, letrozole and 
anastrozole are non-steroidal drugs used for the treatment of cancer.3,4 
In addition, various 1,2,4-triazoles are associated with different biological 
activities. Among 1,2,4-triazole derivatives, mercapto- and thione-substituted 1,2,4- 
-triazole ring systems have been studied and, to date, a variety of antibacterial, 
antifungal,5–7 antitubercular,8,9 anti-inflammatory, analgesic,10,11 antitumoral,12,13 
antiviral14 and anticonvulsant15 properties have been reported for a large number 
of these compounds. 
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Furthermore, diphenyl sulfone derivatives were also found to possess anti-
bacterial activity.16,17 
The incorporation of these two moieties into a single molecule and alkyla-
tion of the –SH group can change the activity of the obtained novel compounds. 
Prompted by the observed biological activities of the above-mentioned com-
pounds and in continuation of ongoing research on the synthesis of heterocyclic 
compounds containing nitrogen and sulfur with expected biological activity,18–21 
the synthesis and characterization of several S-alkylated 1,2,4-triazoles are des-
cribed in this report. All the newly synthesized compounds were characterized by 
IR, UV-Vis, 1H- and 13C-NMR spectroscopy. In addition, the structure of com-
pounds 4a,b, 5b and 6b were confirmed by mass spectrometry. These new com-
pounds were investigated for their antimicrobial activity. 
EXPERIMENTAL 
Materials, methods and instruments 
Commercially available chemicals and solvents were used as received from Sigma-Al-
drich and Merck. The melting points of the new compounds were determined with a Boetius 
apparatus and are uncorrected. The IR spectra (in KBr pellets) were recorded on a Vertex 70 
Bruker spectrometer and the wave numbers are given in cm-1. The NMR spectra were re-
gistered on a Varian Gemini 300 BB spectrometer working at 300 MHz for a 1H and 75 MHz 
for 13C in DMSO-d6 or CDCl3 (10/1, v/v). All chemical shifts are reported in δ (ppm) using 
TMS as the internal standard. The mass spectrum of compound 4a was acquired with a hybrid 
quadrupole – time of flight (QqTOF) high resolution mass spectrometer model API QStar 
Pulsar produced by Applied Biosystems/SCIEX. The instrument was operated in the positive 
ions mode, using an atmospheric pressure pneumatically-assisted electrospray ionization inter-
face (ESI, AB model Turboionspray). The voltage of the mass spectrometer (MS) source was 
set at 5000 V. Molecular ions were detected in full scan over an adequate mass range. Stock 
solutions were prepared at 1 mg/ml in DMSO. The sample solution (2 μg/ml in water/me-
thanol 1/1, v/v) was introduced by direct infusion at a flow rate of 20 μl/min into the MS in-
terface by means of a built-in Harvard syringe pump. The mass spectra of the compounds 4b, 
5b and 6b were registered using a Varian 1200 L/MS/MS triple quadrupole mass spectrometer 
coupled with a high performance liquid chromatograph operating with a Varian ProStar 240 
pump and a Varian ProStar 410 automatic injector. An atmospheric pressure chemical ioniza-
tion interface (APCI) was used in order to obtain the ions. The liquid chromatography was 
performed on a Hypersil Gold (Thermo) column with a pre-column; the mobile phase was 30 
% water and 70 % methanol. The UV-Vis spectra were measurement on a SPECORD 40 
Analytik, Jena, in methanolic solution (2.5×10-5 mol/l). The elemental analyses were perfor-
med with ECS 40-10, COSTEH instrument. 
General procedure for the preparation of new S-alkylated 1,2,4-triazoles 
To a stirred solution of 1,2,4-triazole-3-thione 3a,b (1.0 mmol) and sodium ethoxide (1.0 
mmol of sodium dissolved in 10 mL ethanol) was added the alkylation agent (1.0 mmol). The 
reaction mixture was stirred at room temperature for 12 h, and then poured into ice water. The 
crude product was filtered off, washed with water and recrystallized from ethanol. 
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Biological activity 
The compounds were tested for their in vitro growth inhibitory activity against the 
following Gram-negative bacteria: Acinetobacter baumannii (Ab) ATCC 19606; Citrobacter 
freundii (Cf) ATCC 8090, Escherichia coli (Ec) ATCC 11775 and Pseudomonas aeruginosa 
(Pa)  ATCC 9027, and the following Gram-positive bacteria: Enterococcus faecalis (Ef) 
ATCC 19433, Staphylococcus aureus (Sa) ATCC 12600, Staphylococcus epidermidis (Se) 
ATCC 14990 and Bacillus cereus (Bc) ATCC 14579, using the paper disk diffusion method.22 
Suspensions in sterile peptone water from 24 h cultures of micro-organisms were adjusted to 
0.5 McFarland. Mueller-Hinton Petri dishes of 90 mm diameter were inoculated using these 
suspensions. Paper disks (5 mm in diameter) containing 10 μL of the to be tested substance (at 
a concentration of 2048 μg/mL in DMSO) were placed in a circular pattern in each inoculated 
plate. The plates were incubated at 37 °C for 18–24 h. The inhibitory activity was measured 
(in mm) as the diameter of the observed inhibition zones. The tests were repeated to confirm 
the findings and the average of the readings was taken into consideration. Discs with only 
DMSO were used as the control and ampicillin (10 µg/50µL) served as the control drug. 
RESULTS AND DISCUSSIONS 
Chemistry 
The key intermediates used in the synthesis of the S-alkylated 1,2,4-triazoles, 
the 5-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-(3/4-methylphenyl)-2,4-dihydro-3H- 
-1,2,4-triazole-3-thiones 3a and 3b,23–25 were prepared starting from 4-[(4-bro-
mophenyl)sulfonyl]benzoic acid hydrazide 1.26 The reaction of 1 with 3- or 4-me-
thylphenyl isothiocyanates in refluxing ethanol gave the N1-{4-[(4-bromo-
phenyl)sulfonyl]benzoyl}-N4-(3/4-methylphenyl)thiosemicarbazides (2a,b). 5-{4-
-[(4-Bromophenyl)sulfonyl]phenyl}-4-(3/4-methylphenyl-2,4-dihydro-3H-1,2,4-tri-
azole-3-thiones (3a,b) were synthesized by treating the corresponding thiosemi-
carbazides 2a,b with 8 % NaOH.23,24,27 In the present study, the reaction of the 
1,2,4-triazoles 3a,b with ethyl bromide, phenacyl bromide or ethyl chloroacetate 
in presence of absolute ethanol gave the new S-alkylated triazoles 4–6a,b. 
The synthetic route of the compounds is outlined in Scheme 1. 
Analytical and spectral data of the newly prepared compounds 
3-{4-[(4-Bromophenyl)sulfonyl]phenyl}-5-(ethylthio)-4-(3-methylphenyl)-4H- 
-1,2,4-triazole (4a). Yield: 59 %; m.p. 168–170 °C. Anal. Calcd. for 
C23H20BrN3O2S2 (514.46 g/mol): C, 53.70; H, 3.92; S, 12.47. Found: C, 53.79; 
H, 3.88; S, 12.41. IR (KBr, cm–1): 3084, 3061 (C–H stretching of aromatic ring), 
2972, 2929, 2868 (CH3, CH2 stretching), 1601 (C=N stretching of triazole ring), 
1572, 1460 (C=C-stretching of aromatic ring), 1326, 1160 (SO2 stretching), 576 
(C–Br). 1H-NMR (300 MHz, CDCl3, δ / ppm): 7.98 (1H, br d, aromatic, J = 7.2 
Hz), 7.79 (2H, d, aromatic, J = 8.5 Hz), 7.75 (2H, d, aromatic, J = 8.5 Hz), 7.62 
(4H, d, aromatic, J = 8.5 Hz), 7.30–7.40 (2H, m, aromatic), 7.00 (1H, br s, aro-
matic), 3.29 (2H, q, –SCH2CH3, J = 7.3 Hz), 2.40 (3H, s, –CH3); 1.41 (3H, t,  
–SCH2CH3, J = 7.3 Hz). 13C-NMR (75 MHz, CDCl3, δ / ppm): 154.35 (C3), 
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152.87 (C5), 141.95, 140.69, 140.51, 134.05, 132.66, 131.93, 131.09, 129.97, 129.25, 
128.47, 128.31, 127.79, 127.70, 124.34 (aromatic ring), 26.95 (–SCH2CH3), 
21.17 (–CH3), 14.69 (–SCH2CH3). MS (ESI/QTOF, m/z): 514.0223 [M+H]+, 
516.0165 [M+H]+. UV–Vis (CH3OH) (λmax / nm (log ε)): 207 (4.69), 249 (4.36), 
288 (4.29). 
3-{4-[(4-Bromophenyl)sulfonyl]phenyl}-5-(ethylthio)-4-(4-methylphenyl)-4H- 
-1,2,4-triazole (4b). Yield: 62 %; m.p. 171–173 °C. Anal. Calcd. for 
C23H20BrN3O2S2 (514.46 g/mol): C, 53.70; H, 3.92; S, 12.47. Found: C, 53.62; 
H, 3.85; S, 12.42. IR (KBr, cm–1): 3084, 3057 (C–H stretching of aromatic ring); 
2972, 2929, 2868 (CH3, CH2 stretching), 1599 (C=N stretching of triazole ring), 
1572, 1514 (C=C-stretching of aromatic ring), 1326, 1160 (SO2 stretching), 574 
(C–Br). 1H-NMR (300 MHz, CDCl3, δ / ppm): 7.81 (2H, d, aromatic, J = 8.4 
Hz), 7.76 (2H, d, aromatic, J = 8.4 Hz), 7.63 (2H, d, aromatic, J = 8.4 Hz), 7.58 
(2H, d, aromatic, J = 8.4 Hz), 7.33 (2H, d, aromatic, J = 8.2 Hz), 7.08 (2H, d, 
aromatic, J = 8.2 Hz), 3.29 (2H, q, –SCH2CH3, J = 7.3 Hz), 2.45 (3H, s, –CH3), 
 
Scheme 1. The synthetic route of the title compounds. 
2009 Copyright (CC) SCS
___________________________________________________________________________________________________________________________ Available online at www.shd.org.rs/JSCS/  NEW S-ALKYLATED 1,2,4-TRIAZOLES  1045 
1.42 (3H, t, –SCH2CH3, J = 7.3 Hz). 13C-NMR (75 MHz, CDCl3, δ / ppm): 
154.54 (C3), 152.88 (C5), 141.65, 140.81, 140.74, 140.08, 132.66, 131.10, 130.87, 
129.22, 128.49, 128.03, 127.78, 126.87 (aromatic ring), 26.78 (–SCH2CH3), 
21.32 (–CH3), 14.66 (–SCH2CH3). MS (APCI, m/z): 514 [M+H]+, 516 [M+H]+. 
UV–Vis (CH3OH) (λmax / nm (log ε)): 206 (4.66), 249 (4.35), 287 (4.25). 
2-{[5-(4-((4-Bromophenyl)sulfonyl)phenyl)-4-(3-methylphenyl)-4H-1,2,4-tri-
azol-3-yl]-thio}-1-phenylethanone  (5a). Yield: 81 %; m.p. 189–191 °C. Anal. 
Calcd. for C29H22BrN3O3S2 (604.54 g/mol): C, 57.62; H, 3.67; S, 10.61. Found: 
C, 57.70; H, 3.59; S, 10.56; IR (KBr, cm–1): 3084, 3062 (C–H stretching of 
aromatic ring), 2953, 2922, 2852 (CH3, CH2 stretching), 1681 (C=O stretching), 
1598 (C=N stretching of triazole ring), 1573, 1490 (C=C-stretching of aromatic 
ring), 1324, 1160 (SO2 stretching), 577 (C–Br). 1H-NMR (300 MHz, CDCl3, 
δ / ppm): 8.07 (2H, dd, aromatic, J = 7.9 Hz; 1.5 Hz), 7.82 (2H, d, aromatic, J = 
= 8.5 Hz), 7.76 (2H, d, aromatic, J = 8.6 Hz), 7.64 (2H, d, aromatic, J = 8.6 Hz), 
7.62 (2H, d, aromatic, J = 8.5 Hz), 7.61 (1H, br t, aromatic, J = 7.9 Hz), 7.50 
(2H, t, aromatic, J = 7.9 Hz), 7.41 (1H, t, aromatic, J = 7.9 Hz), 7.36 (1H, br d, 
aromatic, J = 7.9 Hz), 7.05 (2H, m, aromatic), 4.99 (2H, s; –SCH2CO–), 2.41 (3H, 
s, –CH3).  13C-NMR (75 MHz, CDCl3,  δ / ppm): 192.87 (C=O), 153.72 (C3), 
153.15 (C5), 142.14, 140.94, 135.20, 133.88, 133.50, 132.71, 131.60, 131.40, 
130.18, 129.28, 129.08, 129.18, 128.85, 128.72, 128.55, 127.85, 127.60, 124.28 
(aromatic ring), 41.02 (–SCH2CO–), 21.24 (–CH3). UV–Vis (CH3OH) (λmax / nm 
(log ε)): 206 (4.61), 248 (4.40), 285 (4.21). 
2-{[5-(4-((4-Bromophenyl)sulfonyl)phenyl)-4-(4-methylphenyl-4H-1,2,4-tri-
azol-3-yl]-thio}-1-phenylethanone  (5b). Yield: 72 %; m.p. 224–226 °C. Anal. 
Calcd. for C29H22BrN3O3S2 (604.54 g/mol): C, 57.62; H, 3.67; S, 10.61. Found: 
C, 57.72; H, 3.62; S, 10.58. IR (KBr, cm–1): 3063 (C–H stretching of aromatic 
ring), 2960, 2922, 8264 (CH3, CH2 stretching), 1681 (C=O stretching), 1597 
(C=N stretching of triazole ring), 1573, 1513 (C=C-stretching of aromatic ring); 
1323, 1160 (SO2 stretching), 576 (C–Br). 1H-NMR (300 MHz, CDCl3, δ / ppm): 
8.04 (2H, br d, aromatic, J = 7.9 Hz), 7.82 (2H, d, aromatic, J = 8.5 Hz), 7.76 
(2H, d, aromatic, J = 8.5 Hz), 7.63 (2H, d, aromatic, J = 8.5 Hz), 7.60 (1H, br t, 
aromatic, J = 7.9 Hz), 7.58 (2H, d, aromatic, J = 8.5 Hz), 7.49 (2H, br t, aro-
matic, J = 7.9 Hz), 7.32 (2H, d, aromatic, J = 8.2 Hz), 7.13 (2H, d, aromatic, J = 
= 8.2 Hz), 4.98 (2H, s, –SCH2CO–), 2.46 (3H, s, –CH3). 13C-NMR (75 MHz, 
CDCl3, δ / ppm): 192. 96 (C=O), 153.92 (C3), 153.24 (C5), 141.94, 141.15, 141.10, 
140.15, 135.40, 134.07, 132.78, 131.54, 131.14, 129.34, 129.24, 129.20, 128.93, 
128.61, 127.92, 126.92 (aromatic ring), 41.29 (–SCH2CO–), 21.42 (–CH3). MS 
(APCI, m/z): 604 [M+H]+, 606 [M+H]+. UV–Vis (CH3OH) (λmax / nm (log ε)): 
205 (4.68), 248 (4.42), 286 (4.21). 
Ethyl 2-{[5-(4-((4-bromophenyl)sulfonyl)phenyl)-4-(3-methylphenyl)-4H-1,2,4- 
-triazol-3yl]thio}acetate (6a). Yield: 87 %; m.p. 169–170 °C. Anal. Calcd. for 
2009 Copyright (CC) SCS
___________________________________________________________________________________________________________________________ Available online at www.shd.org.rs/JSCS/1046 BARBUCEANU  et al. 
C25H22BrN3O4S2 (572.50 g/mol): C, 52.45; H, 3.87; S, 11.20; Found: C, 52.50; 
H, 3.82; S, 11.17. IR (KBr, cm–1): 3080 (C–H stretching of aromatic ring), 2981, 
2929, 2868 (CH3, CH2 stretching), 1728 (–C=O stretching of –COOH group), 
1599 (C=N stretching of triazole ring), 1572, 1490 (C=C stretching of aromatic 
ring); 1322, 1160 (SO2 stretching), 578 (C–Br). 1H-NMR (CDCl3, δ / ppm): 7.82 
(2H, d, aromatic, J = 8.6 Hz), 7.76 (2H, d, aromatic, J = 8.6 Hz), 7.63 (2H, d, 
aromatic, J = 8.6 Hz), 7.58 (2H, d, aromatic, J = 8.6 Hz), 7.06 (2H, m, aromatic), 
7.38 (2H, m, aromatic), 4.12 (2H, s, –SCH2COO–), 4.22 (2H, q, –COOCH2CH3, 
J = 7.1 Hz), 2.40 (3H, s, –CH3), 1.28 (3H, t, –COOCH2CH3, J = 7.1 Hz). 13C-NMR 
(CDCl3, δ / ppm): 167.99 (–COO), 153.20 (C3), 153.00 (C5), 142.13, 140.88, 
140.43, 133.69, 132.70, 131.68, 131.34, 130.13, 129.28, 128.74, 128.53, 127.83, 
127.62, 124.29 (aromatic ring), 62.01 (–COOCH2CH3), 34.57 (–SCH2COO–), 
21.21 (–CH3), 14.06 (–COOCH2CH3). UV–Vis (CH3OH) (λmax / nm (log ε)): 
206 (4.68), 249 (4.33), 285 (4.32). 
Ethyl 2-{[5-(4-((4-bromophenyl)sulfonyl)phenyl)-4-(4-methylphenyl)-4H-1,2,4- 
-triazol-3yl]thio}acetate (6b). Yield: 67 %; m.p. 209–211 °C. Anal. Calcd. for 
C25H22BrN3O4S2 (572.50 g/mol): C, 52.45; H, 3.87; S, 11.20. Found: C, 52.55; 
H, 3.81; S, 11.25. IR (KBr, cm–1): 3084 (C–H stretching of aromatic ring), 2987, 
2929, 2868 (CH3, CH2 stretching), 1743 (–C=O stretching of –COOH group), 
1599 (C=N stretching of triazole ring), 1572, 1513 (C=C– stretching of aromatic 
ring), 1323, 1161 (SO2 stretching), 576 (C–Br). 
1H-NMR (CDCl3 + DMSO-d6 
(10/1, v/v), δ / ppm): 7.83 (2H, d, aromatic, J = 8.7 Hz), 7.77 (2H, d, aromatic, 
J = 8.6 Hz), 7.64 (2H, d, aromatic, J = 8.6 Hz), 7.60 (2H, d, aromatic, J = 8.7 
Hz), 7.34 (2H, d, aromatic, J = 8.2 Hz), 7.14 (2H, d, aromatic, J = 8.2 Hz), 4.20 
(2H, q, –COOCH2CH3, J = 7.1 Hz), 4.08 (2H, s, –SCH2COO–), 2.47 (3H, s, 
–CH3) 1.28 (3H, t, –COOCH2CH3, J = 7.1 Hz). 13C-NMR (CDCl3 + DMSO-d6 
(10/1, v/v, δ / ppm): 167.82 (–COO), 152.99 (C3), 152.84 (C5), 141.65, 141.25, 
140.83, 140.73, 132.58, 131.33, 130.86, 129.10, 128.64, 128.35, 127.62, 126.67 
(aromatic ring), 61.84 (–COOCH2CH3), 34.21 (–SCH2COO–), 21.17 (–CH3), 
13.93 (–COOCH2CH3). MS (APCI, m/z): 572 [M+H]+, 574 [M+H]+. UV–Vis 
(CH3OH) (λmax / nm (log ε)): 206 (4.61), 249 (4.28), 282 (4.23). 
The spectral data of all the newly synthesized compounds are in full agre-
ement with the proposed structures. 
The infrared absorption spectra of the new S-alkylated 1,2,4-triazoles 4–6a,b 
confirm the alkylation reaction by the disappearance of the stretching of the NH 
group, which appeared at ≈ 3400 cm–1 in the spectra of the triazoles 3a,b.23,24 In 
addition, the absence of the absorption band characteristic of the C=S group, 
which appeared in the spectra of the triazoles 3a,b23,24 at ≈ 1240 cm–1 proved 
that these compounds participated in the alkylation reaction in the thiolic tauto-
meric form and that substitution occurred at the sulfur atom.28 
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The C3 and C5 heterocyclic carbons from the new S-alkylated compounds 
4–6a,b resonated at 152.99–155.54 ppm and 152.88–153.24 ppm, respectively. 
The C3 heterocyclic carbon of these new S-alkylated derivatives is more shielded 
than the C3 heterocyclic carbon from 1,2,4-triazole intermediates 3a,b (δ ≈ 169 
ppm).23,24 These results indicate that the alkylation occurred at the sulfur atom29 
and not at the N2 nitrogen atom. Data from the literature indicated that if the 
alkylation had occurred at the N2 heterocyclic nitrogen, the C3 heterocyclic car-
bon would have resonated at 167–173 ppm.30 
Antimicrobial activity 
The potential antibacterial activity of compounds 2–6 towards eight standard 
strains was investigated. From the data presented in Table I, it may be seen that 
the thiosemicarbazides 2a and 2b showed the highest inhibition zone diameter 
against E. coli, P. aeruginosa, S. aureus and S. epidermidis, compared with the 
other tested compounds. Compounds 2a and 2b showed no inhibitory effects 
against C. freundii and E. faecalis and they were moderately active against A. ba-
umannii and B. cereus. After cyclization of 2a and 2b forming the 1,2,4-triazoles 
3a and 3b, it may be seen how these effects decreased and even completely dis-
appeared in the case of some S-alkylation derivatives. 
TABLE I. Antibacterial activity of the tested compounds (highly active: inhibition zone > 12 
mm; moderately active: inhibition zone 9–12 mm; slightly active: inhibition zone 6–9 mm; 
inactive: inhibition zone < 6 mm) 
Compd. R 
Inhibition zone diameter, mm 
Gram-negative bacteria  Gram-positive bacteria 
Ab Cf Ec Pa  Ef Sa Se Bc 
2a  –C6H4–CH3 (m)  10 – 14  15 – 17  13.5  12 
3a  –C6H4–CH3 (m)  10.5 10 11.5 13  11  12  8  16 
4a  –C6H4–CH3 (m)  9.5  11  – 9 – –  12  14 
5a  –C6H4–CH3 (m)  – 15 – 10 –  –  –  13.5 
6a  –C6H4–CH3 (m)  – 10 –  11.5  –  –  – 15 
2b  –C6H4–CH3 (p)  8  – 16  14 – 18  11.5  10 
3b  –C6H4–CH3 (p)  8 12  12.5  11  11  11 – 15 
4b  –C6H4–CH3 (p)  – 12 –  –  –  –  9 12 
5b  –C6H4–CH3 (p)  – 16 –  –  –  –  –  12.5 
6b  –C6H4–CH3 (p)  – – – – – – –  13 
Ampicillin  –  14  9  10 10 11 15 13 14 
DMSO  –  5 5 5 5 5 5 5 5 
All the tested compounds showed good inhibitory effects against B. cereus. 
Among the S-alkylated triazoles 4–6, the most active compounds were 6a against 
B. cereus (15 mm diameter inhibition zone) and 5b against C. freundii (16 mm 
diameter inhibition zone). This could be explained by electropositive effect of the 
methyl group attached to the phenyl moiety on the heterocyclic ring, which is 
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overlapped the effect of the C=O group inlaid by the S–alkylation reaction and 
together favorably influenced the potency of the heterocyclic nuclei. 
CONCLUSIONS 
This study reports the synthesis of some new S-substituted 1,2,4-triazoles by 
alkylation, in alkaline media, of 5-{4-[(4-bromophenyl)sulfonyl]phenyl}-4-(3/4- 
-methylphenyl)-2,4-dihydro-3H-1,2,4-triazol-3-thiones 3a,b with various alkyla-
tion agents (ethyl bromide, phenacyl bromide and ethyl chloroacetate). The struc-
tures of new compounds were determined from spectral data and elemental ana-
lyses. The potential antibacterial effects of the synthesized compounds, compared 
with those of the parent triazoles and ampicillin, were investigated using different 
standard micro-organisms. The most active compounds were 5b and 6a, which 
exhibited promising activities against C. freundii and B. cereus. Further investi-
gations are in progress. 
ИЗВОД 
НОВИ S-АЛКИЛОВАНИ 1,2,4-ТРИАЗОЛИ КОЈИ САДРЖЕ ДИФЕНИЛСУЛФОНСКЕ 
ГРУПЕ СА ПОТЕНЦИЈАЛНОМ АНТИБАКТЕРИЈСКОМ АКТИВНОШЋУ 
STEFANIA F. BARBUCEANU
1, GABRIELA L. ALMAJAN
1, IOANA SARAMET
1, 
CONSTANTIN DRAGHICI
2, RADU SOCOTEANU
3 и FLORICA BARBUCEANU
4 
1Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Organic Chemistry Department, 
Traian Vuia Street 6, 020956, Bucharest, 
2C. D. Neniţescu Institute of Organic Chemistry, Romanian Academy, 
Splaiul Independenţei 202B, 060023, Bucharest, 
3I. G. Murgulescu Institute of Physical Chemistry, 
Romanian Academy, Splaiul Independentei 202, 77208, Bucharest и 
4Institute for Diagnosis 
and Animal Health, Dr. Staicovici Street 63, 050557, Bucharest, Romania 
Алкиловањем 5-{4-[(4-бромофенил)сулфонил]фенил}-4-(3/4-метилфенил)-2,4-дихидро- 
-3H-1,2,4-триазол-3-тиона (3a,b) алкилујућим реагенсима као што су етил-бромид, фенацил- 
-бромид и етил-хлорацетат добијени су S-супституисани 1,2,4-триазоли 4–6a,b. Структура 
ових нових једињења потврђена је елементалном анализом као и IR, UV, 
1H-NMR, 
13C-NMR 
и MS спектрима. Испитивана је и антибактеријска активност ових једињења. 
(Примљено 29. јануара, ревидирано 22. априла 2009) 
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